GAZYVA (Roche Products Pty Ltd)
Product name
GAZYVA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
147 (255 working days)
Active ingredients
obinutuzumab
Registration type
EOI
Indication
Gazyva is indicated as a pre-treatment to reduce the risk of cytokine release syndrome (CRS) induced by glofitamab.